JP2004059488A - Lactobacillus intestinal disorder controlling composition and food - Google Patents

Lactobacillus intestinal disorder controlling composition and food Download PDF

Info

Publication number
JP2004059488A
JP2004059488A JP2002219233A JP2002219233A JP2004059488A JP 2004059488 A JP2004059488 A JP 2004059488A JP 2002219233 A JP2002219233 A JP 2002219233A JP 2002219233 A JP2002219233 A JP 2002219233A JP 2004059488 A JP2004059488 A JP 2004059488A
Authority
JP
Japan
Prior art keywords
vitamin
lactobacillus
cysteine
lactic acid
controlling composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002219233A
Other languages
Japanese (ja)
Inventor
Shizuo Saito
齋藤 静男
Kazuyuki Ishikawa
石川 和幸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Food and Healthcare Ltd
Original Assignee
Asahi Food and Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Food and Healthcare Ltd filed Critical Asahi Food and Healthcare Ltd
Priority to JP2002219233A priority Critical patent/JP2004059488A/en
Publication of JP2004059488A publication Critical patent/JP2004059488A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a lactobacillus intestinal disorder controlling composition containing reducing components and a lactobacillus and a food product containing the same in the lactobacillus intestinal disorder controlling composition containing the reducing components and the lactobacillus, and to provide its use. <P>SOLUTION: The lactobacillus intestinal disorder controlling composition contains two or more kinds of the reducing components consisting of vitamin C, L-cystine, vitamin B2, vitamin B6, vitamin E, orotic acid, nicotinic acid, pantothenic acid, biotin, glucuronic acid, glutathione and Coix lachryma-jobi L. var. ma-yuen Stapf and the lactobacillus. The reducing components are vitamin C, L-cysteine, vitamin B2, vitamin B6 and vitamin E. <P>COPYRIGHT: (C)2004,JPO

Description

【0001】
【発明の属する技術分野】
本発明は還元性成分および乳酸菌を含む乳酸菌整腸組成物およびその利用に関する。
【0002】
【従来の技術】
ビタミンCなどの還元性成分を含有する食品や薬剤は、抗酸化能を有するため体内の酸化物質の除去および酸化の予防に有効であることが知られている。ビタミンCを用いた健康食品用製剤は、グルコマンナンとビタミンCを主成分とし、これに弱還元性物質を添加したものが出願されている(特開昭60−54321)。また、抗酸化能を上昇させるために、抗酸化性のビタミン剤の多量摂取に代わるものとして天然の抗酸化抗酸化物質と高抗酸化性を有する抗酸化ストレス物が提案されている(特許第2903318号)。
【0003】
【発明が解決しようとする課題】
乳酸菌と還元性成分のビタミンC等を配合した整腸薬では、還元性成分の空気酸化と摂取後に食物に含まれる鉄イオンや銅イオン等による酸化のために酸化型に変化し充分な整腸効果が得られない事がある。
そこで、本発明者は還元性成分の空気酸化や鉄イオンや銅イオン等の遷移金属イオンによる酸化を防ぐことが、より確実な効果を期待するために必要と考えた。
【0004】
【課題を解決するための手段】
本発明は、還元性成分および乳酸菌を含む有産菌組成物である。還元性成分はビタミンC、L−システイン、ビタミンB、ビタミンB、ビタミンE、オロチン酸、ニコチン酸、パントテン酸、ビオチン、グルクロン酸、グルタチオンおよびヨクイニンからなる群から選択される2種以上である。好ましくは還元性成分がビタミンC、L−システイン、ビタミンB、ビタミンBおよびビタミンEである。さらに好ましくは還元性成分がL−システインおよびビタミンCである。さらに本発明は、このような乳酸菌整腸組成物を含有する食品である。
【0005】
乳酸菌としてはL.acidophilus, L.casei, L.gasseri, L.delbrueckii, L.bulgaricus, L.lactis, L.helveticus, L.jugurti, L.fermentum, S.thermophilus, S.lactis, S.faecium, S.faecalis, B.bifidum, B.infantis, B.breve, B.longum等を用いることができる。乳酸菌は整腸作用によって便秘を解消し、さらに吹き出物や肌の調子を整える美肌作用を有する。
【0006】
ビタミンCは食物中の鉄イオンや銅イオンの存在下に急速に酸化される。この酸化は鉄イオンや銅イオンを結合するL−システイン等の還元性成分によって防止することができる。L−システインはビタミンCの酸化を抑える効果がある。また、還元性成分であるL−システインの添加により、比較的安定性が悪いビタミンCの安定化が図られる。よってL−システインおよびビタミンCを含ませた整腸組成物が好ましい。
【0007】
【発明の効果】
本発明の乳酸菌含有の整腸組成物は、還元性成分を含ませたことにより、乳酸菌の生育や整腸等、直接的あるいは間接的に胃腸の調子を整える作用を有する。また、適当な還元性成分を配合することにより、ビタミンC等の還元性ビタミンの酸化による劣化を防止し、これにより確実な整腸効果を得ることができる。
【0008】
【実施例】
以下、実施例により本発明をさらに具体的に説明する。
実施例1(粉末食品)
以下の配合の乳酸菌組成物(混合粉末)を調製した。
乳酸菌(B.longum)60g、ビタミンE 10g、ビタミンC 333g、グルタチオン2gと抹茶1kg、砂糖 100gを混合機にて混合して 1.5kgの粉末混合物を得た。
【0009】
実施例2(粉末ココア飲料)
粉末ココア飲料として以下の配合の乳酸菌組成物(混合粉末)を調製した。
乳酸菌(L.acidophilus, B.longum)の2種を各20g、ビタミンB3g、ビタミンC 333g、L−システイン20gと乾燥ビール酵母 500g、ココア粉末 100g、砂糖 100gを混合機にて混合して 1.5kgの粉末混合物を得た。
【0010】
実施例3(医薬品)
医薬品として以下の配合の乳酸菌組成物(錠剤)を調製した。
ビタミンB2 0.2kg、ビタミンC 7kg、L−システイン 0.4kgと乳糖5kg、コーンスターチ4kg、コリドン 0.5kgを混合機にて混合して流動層造粒器にて造粒し、乾燥後、乳酸菌(L.casei, L.lactis, B.longum)の3種を各0.8kg、ステアリン酸マグネシウム0.1kgの粉末混合物を加え混合後、打錠して錠剤18kgを得た。
【0011】
実施例4(L−アスコルビン酸の酸化抑制試験)
試験方法
▲1▼CuSO・5HO水溶液2ml(Cu:40μgまたは400μg相当)、水18ml、アスコルビン酸水溶液(40mg/10ml)、塩酸システイン水溶液(2.4mg/10ml)を共栓付き遠心沈殿管に正確にとる。この水溶液2mlを正確にとり、メタリン酸(1→20)試液を加え正確に20mlに定容する。共栓付き遠心沈殿管を15分または60分間激しく振り混ぜた後、この水溶液2mlを正確にとり、メタリン酸(1→20)試液を加え正確に20mlに定容する。
【0012】
▲2▼CuSO・5HO水溶液2ml(Cu:40μgまたは400μg相当)、水28ml、アスコルビン酸水溶液(40mg/10ml)を共栓付き遠心沈殿管に正確にとり、同様に操作する。
▲3▼水20ml、アスコルビン酸水溶液(40mg/10ml)、塩酸システイン水溶液(2.4mg/10ml)を共栓付き遠心沈殿管に正確にとり、同様に操作する。
▲4▼アスコルビン酸水溶液(40mg/10ml)20ml、水20mlを共栓付き遠心沈殿管に正確にとり、同様に操作する。
【0013】
試料溶液▲1▼〜▲4▼を各々20μlずつを正確にとり、次の条件で液体クロマトグラフ法により試験を行う。15分または60分間激しく振り混ぜた水溶液について開始時のピークエリアを100%として比較する。
・試験条件
検出器:紫外線吸光光度計(測定波長:254nm)
カラム:Shodex Asahipak NH2P−50 4E(昭和電工(株)、内径4.6×250mm)
カラム温度:40℃付近の一定温度
移動相:アセトニトリル/薄めたリン酸(4→1000)溶液混液(80:20)
流速:L−アスコルビン酸の保持時間が約6分になるように調製する。(1.0ml/分程度)
試験結果
還元型L−アスコルビン酸の酸化は銅イオンの存在下で顕著であり、その酸化はシステインの添加により抑制することを確認した(表1)。
【0014】
【表1】

Figure 2004059488
[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a lactic acid bacteria intestinal composition containing a reducing component and lactic acid bacteria, and use thereof.
[0002]
[Prior art]
It is known that foods and drugs containing reducing components such as vitamin C are effective in removing oxidized substances in the body and preventing oxidation because they have antioxidant ability. A health food preparation using vitamin C has been filed in which glucomannan and vitamin C are the main components and a weakly reducing substance is added thereto (JP-A-60-54321). In addition, in order to increase the antioxidant capacity, natural antioxidant antioxidants and antioxidant stress substances having high antioxidant properties have been proposed as alternatives to large intakes of antioxidant vitamins (Patent No. 1). 2903318).
[0003]
[Problems to be solved by the invention]
Intestinal preparations that contain lactic acid bacteria and reducing component vitamin C, etc., change into oxidized form due to air oxidation of reducing component and oxidation by iron ion or copper ion contained in food after ingestion. The effect may not be obtained.
Therefore, the present inventor considered that it is necessary to prevent oxidation of the reducing component by air oxidation and oxidation by transition metal ions such as iron ions and copper ions in order to expect a more reliable effect.
[0004]
[Means for Solving the Problems]
The present invention is a productive bacterial composition comprising a reducing component and lactic acid bacteria. The reducing component is two or more selected from the group consisting of vitamin C, L-cysteine, vitamin B 2 , vitamin B 6 , vitamin E, orotic acid, nicotinic acid, pantothenic acid, biotin, glucuronic acid, glutathione and yoquinin. is there. Preferably reducing component is Vitamin C, L-cysteine, vitamin B 2, vitamin of B 6 and vitamin E. More preferably, the reducing component is L-cysteine and vitamin C. Furthermore, this invention is a foodstuff containing such a lactic-acid-bacteria intestinal composition.
[0005]
As lactic acid bacteria, L. acidophilus, L.M. casei, L.C. gasseri, L.M. delbrueckii, L .; bulgaricus, L.M. lactis, L.L. helveticus, L.H. jugurti, L.M. fermentum, S.M. thermophilus, S.H. lactis, S .; faecium, S.M. faecalis, B.M. bifidum, B.I. infantis, B.M. breve, B.B. longum or the like can be used. Lactic acid bacteria eliminates constipation by intestinal action, and also has a skin-beautifying action that regulates breakouts and skin tone.
[0006]
Vitamin C is rapidly oxidized in the presence of iron and copper ions in food. This oxidation can be prevented by a reducing component such as L-cysteine that binds iron ions or copper ions. L-cysteine has an effect of suppressing vitamin C oxidation. In addition, the addition of L-cysteine, which is a reducing component, can stabilize vitamin C, which has relatively poor stability. Therefore, an intestinal composition containing L-cysteine and vitamin C is preferred.
[0007]
【The invention's effect】
The lactic acid bacteria-containing intestinal composition according to the present invention has the action of directly or indirectly adjusting the condition of the gastrointestinal tract, such as the growth of the lactic acid bacteria and the intestinal regulation, by including a reducing component. Moreover, by mix | blending a suitable reducing component, deterioration by oxidation of reducing vitamins, such as vitamin C, is prevented, and a reliable intestinal regulation effect can be acquired by this.
[0008]
【Example】
Hereinafter, the present invention will be described more specifically with reference to examples.
Example 1 (powdered food)
A lactic acid bacteria composition (mixed powder) having the following composition was prepared.
Lactic acid bacteria (B. longum) 60 g, vitamin E 10 g, vitamin C 333 g, glutathione 2 g, matcha 1 kg, and sugar 100 g were mixed in a mixer to obtain 1.5 kg of a powder mixture.
[0009]
Example 2 (powdered cocoa beverage)
A lactic acid bacteria composition (mixed powder) having the following composition was prepared as a powdered cocoa beverage.
Lactobacillus (L. acidophilus, B. longum) each 20g of two, vitamin B 2 3 g, vitamin C 333 g, L-cysteine 20g dry brewer's yeast 500 g, by mixing cocoa powder 100g, sugar 100g at mixer 1.5 kg of powder mixture was obtained.
[0010]
Example 3 (Pharmaceuticals)
A lactic acid bacteria composition (tablet) having the following composition was prepared as a pharmaceutical product.
Vitamin B 2 0.2 kg, Vitamin C 7 kg, L-cysteine 0.4 kg and lactose 5 kg, corn starch 4 kg, Kollidon 0.5 kg were mixed in a fluid mixer and granulated in a fluid bed granulator, dried, Three kinds of lactic acid bacteria (L. casei, L. lactis, B. longum) were mixed with a powder mixture of 0.8 kg each and magnesium stearate 0.1 kg, and then tableted to obtain 18 kg of tablets.
[0011]
Example 4 (L-ascorbic acid oxidation inhibition test)
Test method (1) Centrifugal precipitation with a stopper stopper: 2 ml of CuSO 4 · 5H 2 O aqueous solution (Cu: equivalent to 40 μg or 400 μg), 18 ml of water, ascorbic acid aqueous solution (40 mg / 10 ml), cysteine hydrochloride aqueous solution (2.4 mg / 10 ml) Take exactly to the tube. 2 ml of this aqueous solution is accurately taken, and metaphosphoric acid (1 → 20) reagent solution is added to make exactly 20 ml. After vigorously shaking and mixing the centrifugal stopper tube with a stopper for 15 minutes or 60 minutes, 2 ml of this aqueous solution is accurately taken, and metaphosphoric acid (1 → 20) reagent solution is added to make exactly 20 ml.
[0012]
(2) Accurately take 2 ml of CuSO 4 .5H 2 O aqueous solution (Cu: equivalent to 40 μg or 400 μg), 28 ml of water and ascorbic acid aqueous solution (40 mg / 10 ml) in a centrifugal sedimentation tube with a stopper, and operate in the same manner.
(3) Take 20 ml of water, an aqueous ascorbic acid solution (40 mg / 10 ml), and an aqueous cysteine hydrochloride solution (2.4 mg / 10 ml) accurately in a centrifugal sedimentation tube with a stopper, and perform the same operation.
(4) 20 ml of ascorbic acid aqueous solution (40 mg / 10 ml) and 20 ml of water are accurately placed in a centrifugal sedimentation tube with a stopper and the same operation is performed.
[0013]
20 μl of each sample solution (1) to (4) is accurately taken and tested by the liquid chromatograph method under the following conditions. For aqueous solutions shaken vigorously for 15 or 60 minutes, the peak area at the start is set as 100%.
Test condition detector: UV absorption photometer (measurement wavelength: 254 nm)
Column: Shodex Asahipak NH2P-50 4E (Showa Denko KK, inner diameter 4.6 × 250 mm)
Column temperature: constant temperature around 40 ° C. Mobile phase: acetonitrile / diluted phosphoric acid (4 → 1000) solution mixture (80:20)
Flow rate: Prepared so that the retention time of L-ascorbic acid is about 6 minutes. (About 1.0ml / min)
Test results It was confirmed that the oxidation of reduced L-ascorbic acid was significant in the presence of copper ions, and that the oxidation was suppressed by the addition of cysteine (Table 1).
[0014]
[Table 1]
Figure 2004059488

Claims (4)

ビタミンC、L−システイン、ビタミンB、ビタミンB、ビタミンE、オロチン酸、ニコチン酸、パントテン酸、ビオチン、グルクロン酸、グルタチオンおよびヨクイニンからなる還元性成分の群から2種以上および乳酸菌を含む乳酸菌整腸組成物。Contains two or more kinds of reducing components consisting of vitamin C, L-cysteine, vitamin B 2 , vitamin B 6 , vitamin E, orotic acid, nicotinic acid, pantothenic acid, biotin, glucuronic acid, glutathione and yokuinin and lactic acid bacteria Lactic acid bacteria intestinal composition. 還元性成分がビタミンC、L−システイン、ビタミンB、ビタミンBおよびビタミンEである請求項1記載の乳酸菌組成物。Reducing component is Vitamin C, L-cysteine, vitamin B 2, lactic acid bacteria composition of claim 1 wherein the vitamin of B 6 and vitamin E. 還元性成分がL−システインおよびビタミンCである請求項1記載の乳酸菌整腸組成物。The lactic acid bacteria intestinal composition according to claim 1, wherein the reducing components are L-cysteine and vitamin C. 請求項1または2記載の乳酸菌整腸組成物を含有する食品。A food comprising the lactic acid bacteria intestinal composition according to claim 1 or 2.
JP2002219233A 2002-07-29 2002-07-29 Lactobacillus intestinal disorder controlling composition and food Pending JP2004059488A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002219233A JP2004059488A (en) 2002-07-29 2002-07-29 Lactobacillus intestinal disorder controlling composition and food

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002219233A JP2004059488A (en) 2002-07-29 2002-07-29 Lactobacillus intestinal disorder controlling composition and food

Publications (1)

Publication Number Publication Date
JP2004059488A true JP2004059488A (en) 2004-02-26

Family

ID=31940189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002219233A Pending JP2004059488A (en) 2002-07-29 2002-07-29 Lactobacillus intestinal disorder controlling composition and food

Country Status (1)

Country Link
JP (1) JP2004059488A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006014730A (en) * 2004-05-31 2006-01-19 Toyo Shinyaku:Kk Food product
JP2008050325A (en) * 2006-08-28 2008-03-06 Miyarisan Pharmaceutical Co Ltd Digestive tract-cleansing adjuvant containing butyric acid bacterium and/or lactobacillus
JP2012188453A (en) * 2004-12-24 2012-10-04 Meiji Co Ltd Skin improver and method for improving skin
JP2015535280A (en) * 2012-11-01 2015-12-10 レイクスユニフェルシテイト フローニンゲン Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
WO2016065419A1 (en) * 2014-10-28 2016-05-06 Medlab Ip Pty Ltd Treatment for depression and depressive disorders

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02178224A (en) * 1988-11-10 1990-07-11 Ciba Geigy Ag Liquid oral pharmaceuticals
JPH05292947A (en) * 1992-04-17 1993-11-09 Sanei Touka Kk Lactobacillus-acidophilus pn-ri-2-4, lactic acid bacterial formulation using the same and its production
JP2001064174A (en) * 1999-08-23 2001-03-13 Takeda Food Products Ltd Pharmaceutical preparation having synergetically intensified immune activating effect
JP2001169749A (en) * 1999-12-21 2001-06-26 Nitto Yakuhin Kogyo Kk Live bacterium composition
JP2002017254A (en) * 2000-07-10 2002-01-22 Yakult Honsha Co Ltd Light-resistant fermented milk, light-resistant fermented milk product and method for producing the same
JP2002017337A (en) * 2000-05-02 2002-01-22 Biofuerumin Seiyaku Kk Dried microbial cell by spray-drying
JP2002080364A (en) * 2000-09-01 2002-03-19 Takeda Food Products Ltd Immunopotentiating composition
WO2002039834A1 (en) * 2000-11-14 2002-05-23 Societe Des Produits Nestle S.A. Nutritional composition for an immune condition

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02178224A (en) * 1988-11-10 1990-07-11 Ciba Geigy Ag Liquid oral pharmaceuticals
JPH05292947A (en) * 1992-04-17 1993-11-09 Sanei Touka Kk Lactobacillus-acidophilus pn-ri-2-4, lactic acid bacterial formulation using the same and its production
JP2001064174A (en) * 1999-08-23 2001-03-13 Takeda Food Products Ltd Pharmaceutical preparation having synergetically intensified immune activating effect
JP2001169749A (en) * 1999-12-21 2001-06-26 Nitto Yakuhin Kogyo Kk Live bacterium composition
JP2002017337A (en) * 2000-05-02 2002-01-22 Biofuerumin Seiyaku Kk Dried microbial cell by spray-drying
JP2002017254A (en) * 2000-07-10 2002-01-22 Yakult Honsha Co Ltd Light-resistant fermented milk, light-resistant fermented milk product and method for producing the same
JP2002080364A (en) * 2000-09-01 2002-03-19 Takeda Food Products Ltd Immunopotentiating composition
WO2002039834A1 (en) * 2000-11-14 2002-05-23 Societe Des Produits Nestle S.A. Nutritional composition for an immune condition

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006014730A (en) * 2004-05-31 2006-01-19 Toyo Shinyaku:Kk Food product
JP2012188453A (en) * 2004-12-24 2012-10-04 Meiji Co Ltd Skin improver and method for improving skin
JP2008050325A (en) * 2006-08-28 2008-03-06 Miyarisan Pharmaceutical Co Ltd Digestive tract-cleansing adjuvant containing butyric acid bacterium and/or lactobacillus
JP4572185B2 (en) * 2006-08-28 2010-10-27 ミヤリサン製薬株式会社 Gastrointestinal cleansing aid containing butyric acid bacteria and / or lactic acid bacteria
US8597639B2 (en) 2006-08-28 2013-12-03 Miyarisan Pharmaceutical Co., Ltd. Adjunctive agent for lavaging the alimentary canal comprising butyric acid bacterium and/or lactic acid bacterium
JP2015535280A (en) * 2012-11-01 2015-12-10 レイクスユニフェルシテイト フローニンゲン Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
JP2018111711A (en) * 2012-11-01 2018-07-19 レイクスユニフェルシテイト フローニンゲン Riboflavin, riboflavin phosphate, and physiologically acceptable salt thereof
WO2016065419A1 (en) * 2014-10-28 2016-05-06 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
AU2015337800B2 (en) * 2014-10-28 2021-05-27 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
US11135181B2 (en) 2014-10-28 2021-10-05 Medlab Ip Pty Ltd Treatment for depression and depressive disorders

Similar Documents

Publication Publication Date Title
AU2017101478A4 (en) Probiotic compositions and uses thereof for treatment of obesity-related disorders
KR101385864B1 (en) Lactic acid bacteria having action of lowering blood uric acid level
JP5686680B2 (en) Method for producing casein-derived peptide by lactic acid bacteria fermentation
TW200817508A (en) Lactic acid bacterium for amelioration of lactose intolerance
CN106174045A (en) A kind of probiotics fermention calcium-supplementing preparation and preparation method thereof
TWI764598B (en) Reduction of purine content and uric acid level with lactobacillus plantarum tsp05 isolate
EP3479837B1 (en) Renal anemia ameliorating composition
WO2018003900A1 (en) Composition for use in improvement of nutritional state
CN108553406A (en) A kind of composition, its application and with the oral preparation for improving oral health effect
JP5671358B2 (en) Constipation improving agent
WO2021079869A1 (en) Uremic toxin reducing agent
JP6782166B2 (en) Lactic acid bacteria capable of taking up purines and their uses
JP2004059488A (en) Lactobacillus intestinal disorder controlling composition and food
GB2522188A (en) A lactobacillus reuteri GMNL-263 composition for controlling body weight and its use thereof
US20220370522A1 (en) Lactobacillus amylovorus lam1345 isolate, composition including the same and use thereof
JP5631721B2 (en) Gastrointestinal hypersensitizer
EP2419506B1 (en) Bacterial strains having an outstanding ability to produce menaquinone
WO2017057535A1 (en) Deoxycholic acid reduction agent
Abdel Ghany Elrahmany et al. Genetic engineering of UV-mutated Bifidobacterium longum and Lactobacillus acidophilus in relation to folic acid and Anti-inflammatory productivity
EP4133944A1 (en) Composition for improving intestinal bacterial flora
JP2859216B2 (en) Method for producing granules containing useful intestinal bacteria having excellent acid resistance
EP4275682A1 (en) Carbon monoxide-releasing molecule (corm) or composition thereof for use in the treatment or the prevention of an intestinal dysbiosis in a subject
WO2019084616A1 (en) Diagnostic and therapeutic methods for type 2 diabetes
JP5980785B2 (en) New bifidobacteria and their use
EP3517119B1 (en) Composition comprising new lactobacillus salivarius strain and method for the prevention and treatment of otitis and upper respiratory infections

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090310

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090811